AB 278 directs the state health board to set a statewide health care cost target and to define health care sectors (including regions and individual entities) for sector-specific targets, while carving out standards for exemptions. The bill also makes the board responsible for approving the technical rules—methodology and adjustment factors for targets, penalty frameworks and justification factors, spending benchmarks for primary care and behavioral health, goals for alternative payment models (APMs), and workforce stability standards tied to performance plans.
The director must present options and technical work for board discussion: data collection and public reporting approaches, risk-adjustment for per-capita and total expenditure reporting, review processes for performance improvement plans and penalties, analysis of cost drivers (including pharmaceuticals), and strategies to improve affordability and simplify administration. The office may create advisory and technical committees, and the bill requires establishment of a Patient Advocate Advisory Standing Committee with specified representation and reporting duties by June 1, 2026.
At a Glance
What It Does
Requires the board to set statewide and sector-specific health care cost targets, define sectors and exemption criteria, and approve methodologies, penalty regimes, spending benchmarks, APM goals, and workforce standards. It also tasks the director with presenting data, risk‑adjustment, and policy options to inform those decisions.
Who It Affects
Applies to state-level health regulators, payers and providers subject to sector-specific targets (including fully integrated delivery systems unless exempted), patient advocacy groups, and the office that will collect and analyze expenditure and performance data.
Why It Matters
Creates a statutory architecture for price-growth management in California health care: it links targets and enforcement to public reporting, sets incentives for APM adoption, and institutionalizes patient-advocate input — all of which can reshape contracting, compliance, and workforce policy.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
AB 278 sets up a formal process for the board to establish a statewide limit on health care spending growth and to translate that statewide target into specific targets for defined health care sectors. The board must adopt definitions for sectors (which may include geographic regions and individual entities) and decide which providers may be exempt from targets or from direct data submissions.
That creates a two-step structure: a high-level ceiling plus tailored targets for different parts of the system.
Beyond naming targets, the bill puts the board in charge of the technical rules that make targets enforceable: it must approve the method for calculating targets and the factors that adjust them, the scope and rationale for administrative penalties, spending benchmarks for primary care and behavioral health, statewide goals for shifting to alternative payment models, and standards that tie workforce stability to approved performance-improvement plans. These are not advisory checklists—the board’s approvals determine how measurement, incentives, and penalties operate in practice.The director has a central analytical role.
The director must present options on target design (including risk-adjustment approaches), proposals for data collection, public reporting formats, and processes for reviewing and updating performance improvement plans and penalties. The director also brings analyses of cost drivers (explicitly including pharmaceuticals), strategies to make care more affordable for individuals and purchasers, and ideas for administrative simplification and equity- and access-oriented metrics.
That means the board’s policy choices will be driven by technical work the director presents, not only policy preferences.To support those choices the office can run or commission data analyses and must stand up advisory or technical committees when requested by the board. The bill requires one such body: a Patient Advocate Advisory Standing Committee with specified representation from chronic, rare, terminal, and behavioral health advocacy groups.
That committee must meet publicly at least quarterly, accept public comment, and produce an annual report on access, quality, obstacles, and recommendations that the board must include in its own annual report.
The Five Things You Need to Know
The board must establish a statewide health care cost target and may set sector-specific targets (regions, individual entities, and fully integrated delivery systems) after public input.
The board approves the methodology and adjustment factors for targets, plus the scope, range, and justification factors for administrative penalties against entities that miss targets.
The board must adopt benchmarks for primary care and behavioral health spending and set statewide goals and contracting standards to encourage alternative payment models.
The director must present risk‑adjustment approaches, data collection and public reporting plans, analyses of cost drivers (including pharmaceuticals), and review procedures for performance improvement plans to the board.
By June 1, 2026 the bill requires a Patient Advocate Advisory Standing Committee with eight specified advocacy seats that meets at least four times per year, accepts public comment, and issues an annual report for the board to include in its report.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Board duty to set targets, define sectors, and set exemption standards
This provision makes the board the entity that establishes the statewide cost target and defines the sectors to which sector-specific targets apply. It explicitly permits sector definitions to include geographic regions and individual entities and excludes fully integrated delivery systems from the initial sector definition list while allowing target-setting for them. The board must also create standards for when providers can be exempted from targets or direct data submission, which will be the primary tool to limit reporting burdens on certain providers but also creates a gating mechanism that could be contested in practice.
Board approval of methodologies, penalties, benchmarks, APM goals, and workforce standards
This section requires the board to sign off on technical and policy instruments: how targets are computed and adjusted over time; the full architecture for administrative penalties including justification criteria; benchmarks for primary care and behavioral health spending; statewide objectives for alternative payment models and suggested contracting standards; and standards used to promote workforce stability in performance-improvement plan approvals. By centralizing approval authority in the board, the bill channels discretion over measurement and enforcement into a single decision point.
Director’s role: technical presentations and continuous review
The director must bring forward options and technical analysis for the board to discuss—this includes options for target levels, data collection and public reporting designs, risk‑adjustment methodologies for total and per‑capita spending, and procedures for reviewing performance improvement plans and penalties. The director also compiles analyses on cost drivers (including drug costs), affordability strategies for consumers and purchasers, administrative simplification proposals, quality/access/equity metrics, statutory updates to support innovation and APMs, and approaches to market consolidation and power. The provision codifies an ongoing evidence-driven workflow between staff analysis and board decision-making.
Office authority to run analyses and convene technical committees
To support the board, the office can perform or commission data analysis and must establish advisory or technical committees when the board requests them. Committees can be standing or time-limited and must follow membership requirements referenced to another statutory section. The statute contemplates including a mix of health entities, consumer organizations, labor, and patients or caregivers on committees, which means the technical work will be exposed to a broad range of stakeholders but also raises potential conflicts and transparency questions the office will need to manage.
Patient Advocate Advisory Standing Committee: composition, meetings, and reporting
This clause mandates creation of a standing Patient Advocate Advisory Committee by a fixed date and prescribes its membership: two representatives each from advocacy groups for chronic conditions, rare diseases, terminal illnesses, and mental/behavioral health. The committee must meet publicly at least quarterly, accept public comment, and deliver an annual report on obstacles and recommendations to improve access, quality, and affordability for its constituencies; the board must include those recommendations in its annual report. That creates a formalized, recurring channel for patient-centered input into target-setting and policy implementation.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Patients with chronic, rare, terminal, or behavioral health conditions — the mandated Patient Advocate Advisory Committee ensures their access and affordability concerns are formally collected and reported to the board.
- Primary care and behavioral health services — the bill creates explicit spending benchmarks and policy focus on these sectors, increasing the likelihood of resources or incentives flowing toward them.
- Payers and purchasers aiming for predictability — statewide targets and standardized methodologies can provide clearer benchmarks for contracting and budgeting if targets and adjustments are stable and transparent.
Who Bears the Cost
- Health systems and large provider entities (including integrated delivery systems) — they may receive sector-specific targets and face administrative penalties if performance standards are missed, and they will likely shoulder reporting and compliance costs.
- Smaller providers and clinics — unless exempted, they could face new data submission requirements and administrative burdens for responding to performance-improvement plans.
- The state office and board — implementing data collection, risk‑adjustment, committee processes, and adjudicating penalties will require staffing, analytics capacity, and ongoing operational funding.
Key Issues
The Core Tension
AB 278 pits the goal of constraining aggregate health spending growth against the need to preserve access, quality, and provider viability: aggressive targets and penalties can lower costs but risk underinvestment in high‑need services or destabilizing providers, while cautious targets protect providers and services but may fail to restrain cost growth—there is no technical setting that eliminates that trade-off.
The bill centralizes substantive discretion in the board while delegating technical work to the director and the office. That design keeps policy-making at the board level, but it also means the practical impact of targets hinges on the technical choices: how risk adjustment is constructed, which entities are exempted, how penalties are justified and calibrated, and which benchmarks are adopted.
Those technical decisions are complex and can materially change incentives—small differences in risk adjustment or benchmark design can shift costs from one group to another or distort care decisions.
Implementation depends on robust, timely, and high‑quality data. The statute requires public reporting and analytics, but it does not specify data standards, timelines for reporting, or funding to build the necessary infrastructure.
Without clear specifications and resourcing, the office risks producing uneven analyses, delayed reporting, or heavy burdens on providers. Finally, the bill asks the board to address market failures such as consolidation and pharmaceutical costs but provides only a framework rather than concrete remedies; translating analysis into enforceable market interventions will require additional statutory tools or regulatory authority that the bill does not itself create.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.